Your browser doesn't support javascript.
loading
Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
Meyer, Stefan; Stevens, Adam; Paredes, Roberto; Schneider, Marion; Walker, Michael J; Williamson, Andrew J K; Gonzalez-Sanchez, Maria-Belen; Smetsers, Stephanie; Dalal, Vineet; Teng, Hsiang Ying; White, Daniel J; Taylor, Sam; Muter, Joanne; Pierce, Andrew; de Leonibus, Chiara; Rockx, Davy A P; Rooimans, Martin A; Spooncer, Elaine; Stauffer, Stacey; Biswas, Kajal; Godthelp, Barbara; Dorsman, Josephine; Clayton, Peter E; Sharan, Shyam K; Whetton, Anthony D.
Affiliation
  • Meyer S; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Stevens A; Manchester Academic Health Science Centre, Manchester, UK.
  • Paredes R; Department of Paediatric and Adolescent Oncology, Royal Manchester Children's Hospital, Manchester, UK.
  • Schneider M; Young Oncology Unit, Christie Hospital, Manchester, UK.
  • Walker MJ; Manchester Academic Health Science Centre, Manchester, UK.
  • Williamson AJK; Department of Paediatric Endocrinology, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Gonzalez-Sanchez MB; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Smetsers S; Manchester Academic Health Science Centre, Manchester, UK.
  • Dalal V; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Teng HY; Manchester Academic Health Science Centre, Manchester, UK.
  • White DJ; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Taylor S; Manchester Academic Health Science Centre, Manchester, UK.
  • Muter J; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Pierce A; Manchester Academic Health Science Centre, Manchester, UK.
  • de Leonibus C; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Rockx DAP; Manchester Academic Health Science Centre, Manchester, UK.
  • Rooimans MA; Department of Clinical Genetics, Section Oncogenetics, VU University Medical Center, Amsterdam, The Netherlands.
  • Spooncer E; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Stauffer S; Manchester Academic Health Science Centre, Manchester, UK.
  • Biswas K; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Godthelp B; Manchester Academic Health Science Centre, Manchester, UK.
  • Dorsman J; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Clayton PE; Manchester Academic Health Science Centre, Manchester, UK.
  • Sharan SK; Stem Cell &Leukaemia Proteomics Laboratory, Manchester Cancer Research Centre, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine &Health, University of Manchester, Manchester, UK.
  • Whetton AD; Manchester Academic Health Science Centre, Manchester, UK.
Cell Death Dis ; 8(6): e2875, 2017 06 15.
Article in En | MEDLINE | ID: mdl-28617445
ABSTRACT
BRCA2 encodes a protein with a fundamental role in homologous recombination that is essential for normal development. Carrier status of mutations in BRCA2 is associated with familial breast and ovarian cancer, while bi-allelic BRCA2 mutations can cause Fanconi anemia (FA), a cancer predisposition syndrome with cellular cross-linker hypersensitivity. Cancers associated with BRCA2 mutations can acquire chemo-resistance on relapse. We modeled acquired cross-linker resistance with an FA-derived BRCA2-mutated acute myeloid leukemia (AML) platform. Associated with acquired cross-linker resistance was the expression of a functional BRCA2 protein variant lacking exon 5 and exon 7 (BRCA2ΔE5+7), implying a role for BRCA2 splicing for acquired chemo-resistance. Integrated network analysis of transcriptomic and proteomic differences for phenotyping of BRCA2 disruption infers impact on transcription and chromatin remodeling in addition to the DNA damage response. The striking overlap with transcriptional profiles of FA patient hematopoiesis and BRCA mutation associated ovarian cancer helps define and explicate the 'BRCAness' profile.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Alternative Splicing / Drug Resistance, Neoplasm / BRCA2 Protein / Genes, BRCA2 / Mutation Type of study: Risk_factors_studies Limits: Animals / Female / Humans Language: En Year: 2017 Type: Article

Full text: 1 Database: MEDLINE Main subject: Alternative Splicing / Drug Resistance, Neoplasm / BRCA2 Protein / Genes, BRCA2 / Mutation Type of study: Risk_factors_studies Limits: Animals / Female / Humans Language: En Year: 2017 Type: Article